Playback speed
10 seconds
ASCO 2022 IMMUTACE - A Biomarker-Orientated Phase II, Single-Arm, Open-Label AIO Study of Transarterial Chemoembolization + Nivo Performed for Intermediate-Stage HCC: Updated Efficacy Results
By
ASCO 2022 Conference Coverage
FEATURING
Arndt Vogel
By
ASCO 2022 Conference Coverage
FEATURING
Arndt Vogel
89 views
June 15, 2022
Login to view comments.
Click here to Login